Abstract
[...]while the typical presentation of EFT is that of classic ES (i.e., primary tumour of a long bone presenting in childhood; monotonous cytomorphology with diffuse and strong CD99 expression; sensitivity to intensified chemotherapy and radiotherapy), there is significant variability in the histopathological characteristics and clinical behaviour of EFT that remains incompletely described by any association with specific EWSR1 rearrangements[5]. [...]the subset of SRCSs that bear histopathological similarity to EFT but do not harbour EWSR1 fusions have been classified as Ewing-like sarcomas, a heterogeneous group of cancers that frequently exhibit clinical characteristics atypical for classic ES and are associated with primary chemoresistance and poor survival outcomes[2]. [...]there were limits to the sensitivity of PCR-based approaches in detecting fusion transcripts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sarcoma Department, Royal Marsden; Division of Molecular Pathology, Institute of Cancer Research, London
2 Division of Molecular Pathology, Institute of Cancer Research, London
3 Sarcoma Department, Royal Marsden; Division of Clinical Studies, Institute of Cancer Research, London